Long-term efficacy of leptin replacement in patients with familial partial lipodystrophy, Dunnigan variety (FPLD)

被引：0
作者：
Park, Jeany
Javor, Edward D.
Cochran, Elaine K.
Depaoli, Alex M.
Gorden, Phillip
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A18 / A18
页数：1
相关论文
共 50 条
[31]   What is the diagnosis? The patient was clinically diagnosed with familial lipodystrophy associated with the metabolic syndrome. Genetic studies confirmed the presence of type 2 familial partial lipodystrophy syndrome of the Dunnigan variety [J].
Kannan, Subramanian ;
Khanna, Ila ;
Kaur, Manmeet ;
Radin, Michael .
ENDOCRINE PRACTICE, 2011, 17 (04) :665-665
[32]   Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy [J].
Elif A. Oral ;
Phillip Gorden ;
Elaine Cochran ;
David Araújo-Vilar ;
David B. Savage ;
Alison Long ;
Gregory Fine ;
Taylor Salinardi ;
Rebecca J. Brown .
Endocrine, 2019, 64 :500-511
[33]   The liver diseases of lipodystrophy: The long-term effect of leptin treatment [J].
Zadeh, Elika Safar ;
Lungu, Andreea O. ;
Cochran, Elaine K. ;
Brown, Rebecca J. ;
Ghany, Marc G. ;
Heller, Theo ;
Kleiner, David E. ;
Gorden, Phillip .
JOURNAL OF HEPATOLOGY, 2013, 59 (01) :131-137
[34]   Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A/C mutations [J].
Subramanyam, L. ;
Simha, V. ;
Garg, A. .
CLINICAL GENETICS, 2010, 78 (01) :66-73
[35]   Phenotypic gender differences in subjects with familial partial lipodystrophy (Dunnigan variety) due to a nuclear lamin A/C R482W mutation [J].
Araújo-Vilar, D ;
Loidi, L ;
Domínguez, F ;
Cabezas-Cerrato, J .
HORMONE AND METABOLIC RESEARCH, 2003, 35 (01) :29-35
[36]   Long-term efficacy of nelfinavir, adverse events and lipodystrophy [J].
Daniels, E ;
Clotet, B ;
Clax, P ;
Artega, C ;
Nelson, M .
ANTIVIRAL THERAPY, 2004, 9 (06) :L57-L58
[37]   Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2;: MIM 151660) [J].
Lanktree, M. ;
Cao, H. ;
Rabkin, S. W. ;
Hanna, A. ;
Hegele, R. A. .
CLINICAL GENETICS, 2007, 71 (02) :183-186
[38]   Leptin Substitution in Patients With Lipodystrophy: Neural Correlates for Long-term Success in the Normalization of Eating Behavior [J].
Schloegl, Haiko ;
Mueller, Karsten ;
Horstmann, Annette ;
Miehle, Konstanze ;
Pueschel, Janett ;
Villringer, Arno ;
Pleger, Burkhard ;
Stumvoll, Michael ;
Fasshauer, Mathias .
DIABETES, 2016, 65 (08) :2179-2186
[39]   Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy [J].
Ebihara, Ken ;
Kusakabe, Toru ;
Hirata, Masakazu ;
Masuzaki, Hiroaki ;
Miyanaga, Fumiko ;
Kobayashi, Nozomi ;
Tanaka, Tomohiro ;
Chusho, Hideki ;
Miyazawa, Takashi ;
Hayashi, Tatsuya ;
Hosoda, Kiminori ;
Ogawa, Yoshihiro ;
DePaoli, Alex M. ;
Fukushima, Masanori ;
Nakao, Kazuwa .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (02) :532-541
[40]   Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy [J].
Kusakabe, Toru ;
Ebihara, Ken ;
Hirata, Masakazu ;
Masuzaki, Hiroaki ;
Miyanaga, Fumko ;
Kobayashi, Nozomi ;
Tanaka, Tomohiro ;
Hosoda, Kmnori ;
Ogawa, Yoshihiro ;
DePaoli, Alex M. ;
Fukushima, Masanori ;
Nakao, Kazuwa .
DIABETES, 2006, 55 :A472-A472
12345